1-3 of 3
James A. Lederer
Close
Sort by
Journal Articles

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance

Aishath Naeem, Filippo Utro, Qing Wang, Justin Cha, Mauno Vihinen, Stephen Martindale, Yinglu Zhou, Yue Ren, Svitlana Tyekucheva, Annette S. Kim, Stacey M. Fernandes, Gordon Saksena, Kahn Rhrissorrakrai, Chaya Levovitz, Brian P. Danysh, Kara Slowik, Raquel A. Jacobs, Matthew S. Davids, James A. Lederer, Rula Zain, C. I. Edvard Smith, Ignaty Leshchiner, Laxmi Parida, Gad Getz, Jennifer R. Brown
Journal: Blood Advances
Blood Adv (2023) 7 (9): 1929–1943.
https://doi.org/10.1182/bloodadvances.2022008447
Published: 2023
Includes: Supplemental data
Journal Articles

Inflammasome activation in neutrophils of patients with severe COVID-19

Karen Aymonnier, Julie Ng, Laura E. Fredenburgh, Katherin Zambrano-Vera, Patrick Münzer, Sarah Gutch, Shoichi Fukui, Michael Desjardins, Meera Subramaniam, Rebecca M Baron, Benjamin A. Raby, Mark A. Perrella, James A. Lederer, Denisa D. Wagner
Journal: Blood Advances
Blood Adv (2022) 6 (7): 2001–2013.
https://doi.org/10.1182/bloodadvances.2021005949
Published: 2022
Includes: Multimedia, Supplemental data
Journal Articles

Augmenting emergency granulopoiesis with CpG conditioned mesenchymal stromal cells in murine neutropenic sepsis

Julie Ng, Fei Guo, Anna E. Marneth, Sailaja Ghanta, Min-Young Kwon, Joshua Keegan, Xiaoli Liu, Kyle T. Wright, Baransel Kamaz, Laura A. Cahill, Ann Mullally, Mark A. Perrella, James A. Lederer
Journal: Blood Advances
Blood Adv (2020) 4 (19): 4965–4979.
https://doi.org/10.1182/bloodadvances.2020002556
Published: 2020
Includes: Supplemental data